DNA X, Inc. (SONM): Nasdaq/NYSE listing notice — Sonim Technologies gets Nasdaq extension to Sept 9, 2024 to meet $1 bid price rule

DNA X, Inc.

Nasdaq granted Sonim additional 180 days, until Sept 9, 2024, to comply with $1 minimum bid price (Nasdaq Rule 5550(a)(2)).
Company must achieve closing bid price >=$1 for ten consecutive business days before Sept 9, 2024.
If noncompliant by deadline, Nasdaq will issue delisting notice; Sonim may appeal to a Hearings Panel.
Common stock continues trading on Nasdaq Capital Market under symbol SONM during the extension.
Sonim is evaluating options including a reverse stock split, but compliance is not assured.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

DNA X, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 13, 2024, Sonim Technologies, Inc. (the “Company”) received formal notice that The Nasdaq Stock Market, LLC (“Nasdaq”) granted the Company’s request for an additional 180-day period, or until September 9, 2024, (the “Extension Notice”) from the Listing Qualifications Department (the “Staff”) to evidence compliance with the $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). If at any time before September 9, 2024, the bid price of the Company’s common stock closes at $1.00 per share or

View on SEC.gov

Browse all listing & compliance notices →

DNA X, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-009975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.